-
1
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX...
Published 2024-01-01Subjects: “…HLX01…”
Get full text
Article